| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| I412009-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $23.90 | |
| I412009-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $119.90 | |
| I412009-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $279.90 | |
| I412009-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $419.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Infliximab (anti-TNF-alpha), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to TNFSF2/TNFa, >95%, high purity, Human IgG1 |
|---|---|
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | TNFSF2/TNFa |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of TNF-alpha inhibitor |
| Product Description | Infliximab (anti-TNF-alpha) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α, prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2), has the potential for treatment of Crohn's disease and rheumatoid arthritis. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 27.6 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 186.7 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 170277-31-3 |
Infliximab (anti-TNF-alpha) (I412009) - ELISA
Immobilized Recombinant Human TNF-alpha Protein (rp156007) at 0.5 μg/mL can bind Infliximab (anti-TNF-alpha) (I412009) with the EC₅₀ of 31.52 ng/mL.
Infliximab (anti-TNF-alpha) (I412009) - SEC
The purity of Infliximab (anti-TNF-alpha) (I412009) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Wikipedia | Infliximab |
|---|---|
| IMGT/mAb-DB | 156 |
| PEP | infliximab |
| Immunopaedia Search | infliximab |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F0900976 | Certificate of Analysis | Sep 06, 2023 | I412009 |
| ZJ23F0900975 | Certificate of Analysis | Sep 06, 2023 | I412009 |
| 1. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL et al.. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.. Gastroenterology, 117 (4): (761-9). [PMID:10500056] [10.1021/op500134e] |
| 2. Blair HA, Deeks ED. (2016) Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.. BioDrugs, 30 (5): (469-480). [PMID:27650650] [10.1021/op500134e] |
| 3. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B et al.. (2017) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.. Ann Rheum Dis, 76 (2): (355-363). [PMID:27130908] [10.1021/op500134e] |
| 4. Derzi M, Johnson TR, Shoieb AM, Conlon HD, Sharpe P, Saati A, Koob S, Bolt MW, Lorello LG, McNally J et al.. (2016) Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab).. Adv Ther, 33 (11): (1964-1982). [PMID:27585978] [10.1021/op500134e] |
| 5. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).. Gastroenterology, 109 (1): (129-35). [PMID:7797011] [10.1021/op500134e] |
| 6. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.. Biochim Biophys Acta, 1812 (8): (982-94). [PMID:21193033] [10.1021/op500134e] |
